RLIP76 in Human Serum in Adults With Rheumatologic Diseases

This study has been withdrawn prior to enrollment.
(Study withdrawn due to lack of staffing resources and subject interest)
Sponsor:
Information provided by:
University of North Texas Health Science Center
ClinicalTrials.gov Identifier:
NCT00861159
First received: September 29, 2008
Last updated: January 11, 2011
Last verified: January 2011
  Purpose

It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").


Condition
Carotid Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.

Resource links provided by NLM:


Further study details as provided by University of North Texas Health Science Center:

Primary Outcome Measures:
  • The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera. [ Time Frame: three years ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: September 2011
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)

Detailed Description:

This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The experimental populations subject to study will be 100 outpatients in the rheumatology clinic otherwise undergoing routinely scheduled phlebotomy for standard clinical care purposes.

Criteria

Inclusion Criteria:

  • Adult (age 18+), non-pregnant subjects with previously diagnosed rheumatologic disease will be candidates for the study.

Exclusion Criteria:

  • Children, pregnant women, prisoner, persons with any medical condition that precludes phlebotomy, and patients unwilling or unable to provide consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00861159

Locations
United States, Texas
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76109
Sponsors and Collaborators
University of North Texas Health Science Center
Investigators
Principal Investigator: Sanjay Awasthi, MD University of North Texas Health Science Center
  More Information

Publications:
Responsible Party: Measurement of RLIP76 Auto Antibodies in Human Serum in Adults with Rheumatologic Disease., University of North Texas Health Science Center
ClinicalTrials.gov Identifier: NCT00861159     History of Changes
Other Study ID Numbers: 2008-31
Study First Received: September 29, 2008
Last Updated: January 11, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of North Texas Health Science Center:
RLIP76 Auto Antibodies

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Carotid Artery Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Autoantibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014